 |
59 Diseases |  |
24 Trials |
|
24 Trials |  |
1999 News |  |
| «12...1112131415161718192021...2526» |
- | Vimpat (lacosamide) / UCB, Daiichi Sankyo, pentylenetetrazole (BTD-001) / Balance Therap
Preclinical, Journal: Evaluation of the impact of compound C11 a new anticonvulsant candidate on cognitive functions and hippocampal neurogenesis in mouse brain. (Pubmed Central) - Jan 6, 2021
C11 revealed high efficacy in acute animal seizure models such as the maximal electroshock model (MES), the pentylenetetrazole model (PTZ) and the 6 Hz (6 Hz, 32 mA) seizure model, as well as in the kindling model of epilepsy induced by repeated injection of PTZ in mice...The following drugs were used: C11, levetiracetam (LEV), ethosuximide (ETS) and lacosamide (LCM)...A new hybrid compound C11 in contrast to LCM has no negative impact on the process of neurogenesis and neurodegeneration in the mouse hippocampus. Furthermore, chronic treatment with C11 turned out to have no negative impact on cognitive functions of treated mice, which, is certainly of great importance for further more advanced preclinical and especially clinical trials.
- || Vimpat (lacosamide) / UCB, Daiichi Sankyo
Clinical, Journal: Lacosamide Levels in Blood and Breastmilk During Pregnancy and Lactation: A Case Report. (Pubmed Central) - Dec 30, 2020
Furthermore, chronic treatment with C11 turned out to have no negative impact on cognitive functions of treated mice, which, is certainly of great importance for further more advanced preclinical and especially clinical trials. No abstract available
- | lacosamide / Generic mfg.
Trial completion date, Trial primary completion date: Lacosamide Effects on Alcohol Self Administration and Craving in Heavy Drinkers (clinicaltrials.gov) - Dec 28, 2020
P1, N=28, Suspended, Sponsor: Boston Medical Center
No abstract available Trial completion date: Dec 2020 --> Mar 2021 | Trial primary completion date: Dec 2020 --> Mar 2021
- Vimpat (lacosamide) / UCB, Daiichi Sankyo
[VIRTUAL] Safety and Efficiency of Intravenous Push versus Intravenous Piggyback with Levetiracetam and Lacosamide () - Dec 26, 2020 - Abstract #ASHP2020ASHP_5036;
Lacosamide safety outcomes were evaluated for hypotension (SBP less than 90mmHg), bradycardia (HR less than 60 BPM), and infusion-related reactions within two hours of administration. Levetiracetam safety outcomes were assessed for injection site pain and discomfort, erythema, extravasation, and intravenous line replacement leading to IV levetiracetam discontinuation.
- Tirosint (levothyroxine) / IBSA Institute Biochemical SA
[VIRTUAL] Re-evaluation of intravenous to oral route conversion policy for antiepileptic medications, vitamins and levothyroxine () - Dec 26, 2020 - Abstract #ASHP2020ASHP_4211;
Any additional IV doses given past the eligible conversion time will be considered inappropriate and associated with a cost. Descriptive statistics will be used for analysis.
- Vimpat (lacosamide) / UCB, Daiichi Sankyo
[VIRTUAL] Evaluation of safety outcomes of levetiracetam and lacosamide intravenous push compared to intravenous piggyback () - Dec 26, 2020 - Abstract #ASHP2020ASHP_3959;
Secondary outcomes will include material costs. Primary safety outcomes for both lacosamide and levetiracetam will include infusion site reactions and bradycardia and PR prolongation for lacosamide.
- milrinone / Generic mfg.
[VIRTUAL] Milrinone for cerebral vasospasm following aneurysmal subarachnoid hemorrhage () - Dec 26, 2020 - Abstract #ASHP2020ASHP_3418;
A combination of intra-arterial verapamil and intravenous milrinone was started to manage CVS and maintain cardiac output...Per AHA/ASA 2012 guidelines, he was started on oral nimodipine and underwent emergent endovascular repair with aneurysmal coiling...After a 32 day length of stay, the patient was discharged to a rehabilitation facility on aspirin and simvastatin, as well as levetiracetam and lacosamide for seizure prevention...Based off of limited data, milrinone appears to be a safe intervention for CVS in patients with aSAH. Further studies are needed to establish the efficacy and safety of milrinone treatment for CVS.
- Flagyl (metronidazole) / SLA
[VIRTUAL] Refractory seizures secondary to neurocysticercosis () - Dec 26, 2020 - Abstract #ASHP2020ASHP_2914;
In ED, she had two more GTCS which required lorazepam for the first episode and repeat of lorazepam with an increase in propofol for the second episode...She was started on ceftriaxone and metronidazole for empiric treatment of post-partum endometritis...The patient was started on albendazole and dexamethasone...This case represents a rare status epilepticus refractory to neurocysticercosis with a patient that was in remission for ten years. It is important to consider neurocysticercosis on the differential in any patient presenting with status epilepticus.
- Trileptal (oxcarbazepine) / Novartis
[VIRTUAL] Evaluation of antiepileptic medication level monitoring in the inpatient setting. () - Dec 26, 2020 - Abstract #ASHP2020ASHP_2007;
The primary outcomes for this evaluation are the percentage of patients receiving an antiepileptic medication who had a trough drawn and the percentage of patients with a trough drawn properly. Data collection will begin once the evaluation has been submitted to and approved by the IRB.
- Vimpat (lacosamide) / UCB, Daiichi Sankyo
[VIRTUAL] Efficiency and Safety of Undiluted Intravenous Push Levetiracetam and Lacosamide () - Dec 26, 2020 - Abstract #ASHP2020ASHP_1928;
The primary outcome is the time from order entry to medication administration of the initial AED dose ordered for immediate use. Secondary outcomes include time from order entry to pharmacist verification, time from pharmacist verification to medication administration, rate of overdue doses, rate of adverse drug reactions (hypotension, bradycardia, and infusion reactions), and cost.
- Humira (adalimumab) / Eisai, AbbVie, Trileptal (oxcarbazepine) / Novartis
[VIRTUAL] The clinical use of immunosuppressants and anti-epileptic drug therapies in the treatment of Neuro-Behcet's in a patient with unspecified dementia and epileptic seizure () - Dec 26, 2020 - Abstract #ASHP2020ASHP_1699;
Treatment was initiated with haloperidol, loxapine, lorazepam, phenytoin, levetiracetam, topiramate, lacosamide, adalimumab, hibiclens, and theragran...For ulcers, PD4 inhibitor apremilast is the only FDA approved medication...Anti-epileptic drugs (AED) phenytoin, oxcarbazepine or carbamazepine can control seizures in most patients...Although the combination of dementia, epilepsy and intellectual disabilities seen together in this patient is rare, it is a predictable complication of NBD. Recognition of these symptoms is critical to initiating appropriate therapy.
- || Vimpat (lacosamide) / UCB, Daiichi Sankyo
Clinical, Journal: Tolerability of lacosamide rapid dose titration: A randomized, multicenter, prospective, open-label study. (Pubmed Central) - Dec 22, 2020
Rapid titration protocols for lacosamide were not associated with an increased risk of adverse events compared to the conventional weekly titration protocol. Uptitration of lacosamide at shorter intervals to an effective target dosage may be feasible in appropriate clinical situations.
- || pregabalin / Generic mfg.
Clinical, PK/PD data, Review, Journal: Pharmacodynamic interactions of antiepileptic drugs: From bench to clinical practice. (Pubmed Central) - Dec 18, 2020
The pharmacodynamic lamotrigine-valproate interaction is also supported by synergistic adverse events. Therefore, well-designed double-blind prospective studies recruiting a sufficient number of patients possibly with a crossover design and carefully ascertain the role of pharmacokinetic interactions and variations of AEDs' levels in the blood are needed.
- || Vimpat (lacosamide) / UCB, Daiichi Sankyo
Clinical, Journal: The effect of lacosamide on psychiatric comorbidities in patients with epilepsy. (Pubmed Central) - Dec 17, 2020
LCM polytherapy may have less negative influence on psychiatric comorbidities in patients with epilepsy compared with other antiseizure medications, and may also improve seizure severity. While LCM polytherapy might improve psychiatric symptoms as seizures improve, a small number of patients experienced worsening of psychiatric symptoms despite seizure improvement.
- || Clinical, Journal: Praxis-induced reflex seizures in two Japanese cases with ring chromosome 20 syndrome. (Pubmed Central) - Dec 17, 2020
In both cases, the hyperexcitability in the frontal lobe may have spread to the motor cortex and precipitated praxis-induced seizures. Therefore, in addition to the known characteristic triad, praxis-induced reflex seizures may also be a feature of ring chromosome 20 syndrome.
- || Vimpat (lacosamide) / UCB, Daiichi Sankyo, Fycompa (perampanel) / Eisai, lamotrigine liquid oral suspension / OWP Pharma
Clinical, Journal: Ictal electroencephalography (EEG) activity and cerebral blood flow dynamics as potential pathological indicators: a case of anti-leucine-rich glioma-inactivated 1 protein (LGI1) encephalitis (Pubmed Central) - Dec 15, 2020
Temporal change in ASL imaging suggested that the hyper perfusion in ASL during the acute stage could be provided by inflammation of the encephalitis its self and also the seizures activities (FBDS and FIAS). The pathophysiological indication of anti-LGI1 encephalitis was limited in terms of the therapeutic strategy, however, our findings collectively suggested that the combination analysis of EEG activity and cerebral blood flow dynamics (ASL) could be the potential candidate.
- | Vimpat (lacosamide) / UCB, Daiichi Sankyo
Journal: Lacosamide intake during pregnancy increases the incidence of foetal malformations and symptoms associated with schizophrenia in the offspring of mice. (Pubmed Central) - Dec 2, 2020
Neonatal mice born to dams treated with LCM during gestation displayed clear psychomotor delay and behavioural and morphological alterations in the prefrontal cortex, hippocampus and amygdala that were associated with behaviours associated with schizophrenia spectrum disorders in adulthood. We conclude that LCM and its metabolites may have teratogenic effects on the developing embryos, reflected in embryonic lethality and malformations, as well as behavioural and histological alterations in adult mice that resemble those presented by patients with schizophrenia.
- | Vimpat (lacosamide) / UCB, Daiichi Sankyo, Aptiom (eslicarbazepine) / Sumitomo Dainippon, Eisai
Journal: Initiating antiepilepsy treatment: An update of expert consensus in Spain. (Pubmed Central) - Nov 28, 2020
With respect to the choice of initial monotherapy depending on the type of epilepsy and the patient's age/sex profile, it is agreed to avoid valproic acid (VPA) in women with childbearing potential, with levetiracetam (LEV) and lamotrigine (LTG) being the preferable options in generalized epilepsy...In the elderly, LEV, lacosamide (LCM), eslicarbazepine acetate (ESL) and LTG are considered the most suitable drugs for initiating treatment...In conclusion, as the ILAE definition states, there are different situations that lead to treatment initiation after a first seizure. When choosing the first ASM, the type of epilepsy, childbearing potential and drug-drug interaction are key factors.
- Vimpat (lacosamide) / UCB, Daiichi Sankyo, Cerebyx (fosphenytoin) / Pfizer, Nobelpharma
[VIRTUAL] Multilobar focal cortical dysplasia type IIA in a child presenting with Febrile Infection-Related Epilepsy Syndrome (FIRES) () - Nov 28, 2020 - Abstract #AES2020AES_1299;
The significance of the newly described co-occurrence of FIRES and the focal cortical dysplasia merits further investigation. Funding: None
- Vimpat (lacosamide) / UCB, Daiichi Sankyo
[VIRTUAL] Safety of adjunctive lacosamide in patients with primary generalized tonic-clonic seizures (PGTCS) and patients with focal seizures: pooled data for pediatrics and adults () - Nov 28, 2020 - Abstract #AES2020AES_1240;
P2, P3
Safety observations in patients with PGTCS were generally consistent with the known safety profile of LCM in patients with focal seizures. Funding: UCB Pharma-sponsoredFIGURESFigure 1Figure 2
- Vimpat (lacosamide) / UCB, Daiichi Sankyo
[VIRTUAL] Long-term safety and efficacy of adjunctive lacosamide in the treatment of primary generalized tonic-clonic seizures: an open-label extension trial () - Nov 28, 2020 - Abstract #AES2020AES_1239;
P3
No new safety concerns were identified. Reductions in PGTCS frequency were observed and few patients had worsening of PGTCS, myoclonic, or absence seizures.
- ganaxolone IV / Marinus
[VIRTUAL] IV Ganaxolone in Pediatric Super-Refractory Status Epilepticus: A Single Patient Case Study () - Nov 28, 2020 - Abstract #AES2020AES_1237;
It is a 3β-methylated synthetic analog of the endogenous progesterone metabolite, allopregnanolone. GNX differs from other GABA agents by interacting with both synaptic and extrasynaptic GABAA receptors and at binding sites distinct from benzodiazepines or barbiturates.
- Trileptal (oxcarbazepine) / Novartis
[VIRTUAL] Cognitive burden of anti-seizure medications: a language functional MRI perspective () - Nov 28, 2020 - Abstract #AES2020AES_1188;
Levetiracetam showed less effect on cognitive activation patterns than were other frequently prescribed ASMs. Combination therapy and a higher drug load were associated with impairment of cognitive activation patterns.
- pregabalin / Generic mfg.
[VIRTUAL] Efficacy of 250 antiseizure drug combinations in a zebrafish model of Dravet Syndrome () - Nov 28, 2020 - Abstract #AES2020AES_1135;
Alternative combinations of ASD therapies might be efficacious for monogenic intractable epilepsies. Funding: None
- Vimpat (lacosamide) / UCB, Daiichi Sankyo
[VIRTUAL] Efficacy of adjunctive lacosamide in the treatment of primary generalized tonic-clonic seizures: subgroup analyses of a double-blind, randomized, placebo-controlled trial () - Nov 28, 2020 - Abstract #AES2020AES_1043;
P3
Efficacy findings in all subgroups were consistent with the overall population. Funding: UCB Pharma-sponsored
- carbamazepine / Generic mfg.
[VIRTUAL] Subject-specific factors are correlated with intracranial interictal epileptiform discharges in refractory epilepsy () - Nov 28, 2020 - Abstract #AES2020AES_1005;
Our findings confirmed, with intracranial recordings, that IED rates were higher in regions near SOZs relative to regions distant from SOZs. They also suggest that IED rates may be a new metric to consider when assessing ASM efficacy.
- lamotrigine liquid oral suspension / OWP Pharma
[VIRTUAL] A Case of Ictal Asystole in Temporal Lobe Epilepsy () - Nov 28, 2020 - Abstract #AES2020AES_945;
Left TLE in particular is associated with autonomic-induced cardiorespiratory phenomena such as ictal bradycardia and ictal central apnea, due to the role of the left insular region in parasympathetic regulation demonstrated through cortical stimulation and lesional studies. 2, 3.
- carbamazepine / Generic mfg.
[VIRTUAL] Administration of Selected Sodium Channel- Blocking Antiseizure Drugs Alters the Development of Pharmacoresistant Kindled Seizures () - Nov 28, 2020 - Abstract #AES2020AES_939;
This study suggests that early, chronic administration of fast-inactivation state preferring ASDs, such as lamotrigine, versus slow-inactivation state preferring ASDs, like LCM, early in the kindling process may significantly alter the development of pharmacoresistance in the corneal kindled mouse model of chronic neuronal hyperexcitability. Funding: NCATS KL2 TR002317 to MBH
- Briviact (brivaracetam) / UCB
[VIRTUAL] Brivaracetam: Long term experience in Mexico () - Nov 28, 2020 - Abstract #AES2020AES_905;
B: Patients on levetiracetam (LVT) treatment and switched to brivaracetam due to undesirable adverse events...The most common and useful combination was with lacosamide...The primary adverse effect was a long-lasting drowsy-lethargic state, which impeded patients' daily activities. Funding: No funding was required for this study
- Xcopri (cenobamate) / SK Biopharmaceuticals, Arvelle Therap
[VIRTUAL] Efficacy of Cenobamate by Concomitant Antiseizure Medications in Patients With Uncontrolled Focal Seizures: Post-hoc Analysis of a Phase 3, Multicenter, Open-Label Study () - Nov 28, 2020 - Abstract #AES2020AES_830;
Relevant clinical outcomes were generally consistent by baseline ASM. The AE profile of the combinations was consistent with the known profiles of these ASMs, and no new tolerability issues were identified.
- Xcopri (cenobamate) / SK Biopharmaceuticals, Arvelle Therap, Trileptal (oxcarbazepine) / Novartis
[VIRTUAL] Dose Adjustments to Concomitant Antiseizure Medications: Post-hoc Analysis of a Phase 3, Open-Label Study of Cenobamate for the Treatment of Uncontrolled Focal Seizures () - Nov 28, 2020 - Abstract #AES2020AES_646;
Decreasing doses of phenytoin, clobazam, and lacosamide were the earliest clinically performed. Funding: SK Life Science, Inc.
- Vimpat (lacosamide) / UCB, Daiichi Sankyo
[VIRTUAL] Levetiracetam, Lamotrigine, Lacosamide and Topiramate monotherapy; Database Analysis from an Epilepsy Center () - Nov 28, 2020 - Abstract #AES2020AES_639;
Lamotrigine monotherapy was associated with the highest seizure free rate. Dropout rates were the highest for topiramate compared to the other three ASM.
- Trileptal (oxcarbazepine) / Novartis
[VIRTUAL] Corpus Callosotomy and Intracranial Electroencephalogram: Multi-Staged Diagnostic Procedure for Epileptogenic Focus Lateralization and Localization in Medically Refractory Focal Epilepsy Syndrome for Epilepsy Surgery () - Nov 28, 2020 - Abstract #AES2020AES_593;
While CC has no therapeutic benefit in focal epilepsy syndromes, it has emerged with diagnostic value. Only a few studies have discussed the role of CC and iEEG, as a multi-staged diagnostic procedure for the lateralization and localization of an epileptogenic focus prior to epilepsy surgery.
- Trileptal (oxcarbazepine) / Novartis
[VIRTUAL] Hypothalamic hamartoma and epilepsy in a NYC based population: results from RENYC () - Nov 28, 2020 - Abstract #AES2020AES_586;
Of particular clinical interest is the frequent presence of seizures without EEG correlate, high association with developmental impairments, and occasional association with other congenital anomalies. ASMs are generally ineffective in controlling these seizures.
- Vimpat (lacosamide) / UCB, Daiichi Sankyo
[VIRTUAL] Central Apnea and Seizures in a COVID-19 Pediatric Patient () - Nov 28, 2020 - Abstract #AES2020AES_499;
It remains to be seen whether COVID-19 may precipitate an increase in SUDEP in patients with epilepsy. Funding: No funding received.
- sertraline / Generic mfg.
[VIRTUAL] New-onset Binge Eating Disorder After Anterior Temporal Lobe Resection with Amygdalohippocampectomy () - Nov 28, 2020 - Abstract #AES2020AES_465;
Overeating to relieve negative affective states and overeating despite aversive consequences have been related to amygdala function. In our patient, with a psychiatric history but no history of eating disorder, amygdalohippocampectomy with anterior temporal lobectomy led to abrupt onset, clinically significant binge-eating that was refractory to medical management and psychologic interventions.
- Vimpat (lacosamide) / UCB, Daiichi Sankyo
[VIRTUAL] Lacosamide and Levetiracetam for the treatment of Non-Convulsive Status Epilepticus () - Nov 28, 2020 - Abstract #AES2020AES_324;
However, levetiracetam was found to be more effective when given as a third line agent or later. Our study shows lacosamide to be valid as a therapeutic option in the treatment of NCSE as compared with levetiracetam.
- Vimpat (lacosamide) / UCB, Daiichi Sankyo
[VIRTUAL] Safety and Tolerability of Lacosamide for Neonatal Seizures in Preterm Infants () - Nov 28, 2020 - Abstract #AES2020AES_311;
Preliminary analysis of vEEG data shows a trend towards a greater than 50% decrease in seizure burden after LCS administration. Prospective randomized clinical trials are needed to further characterize its efficacy in preterm and term infants.
- [VIRTUAL] Prescribing errors of high carbohydrate medications for children on the Ketogenic Diet () - Nov 28, 2020 - Abstract #AES2020AES_302;
A CDS system embedded within the EMR identified only 21% of errors occur in designated in-patient neurology units. Most errors occurred in other areas of the hospital.
- Actemra IV (tocilizumab) / Roche, JW Pharma, Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche, Trileptal (oxcarbazepine) / Novartis
[VIRTUAL] New Onset Refractory Status Epilepticus treated successfully with Tocilizumab () - Nov 28, 2020 - Abstract #AES2020AES_299;
Many recent studies have identified cytokines associated with poorly controlled epilepsy. Recent research has shown that uncontrolled seizures lead to an inflammatory cascade, with rising IL-6 levels, blood-brain barrier disruption and seizure propagation.
- Rituxan (rituximab) / Biogen, Zenyaku Kogyo, Roche
[VIRTUAL] Electroconvulsive therapy as a last resort for suprarefractory status epilepticus in a patient with severe NMDA-R-Ab autoimmune encephalitis and decompression hemicraniectomy () - Nov 28, 2020 - Abstract #DGN2020DGN_513;
Even if there are indications from case series of a possible effectiveness of ECT in SRSE, there is no evidence both prospective data on the effectiveness of ECT in SRSE and clear recommendations on therapy escalation beyond the use of general anesthetics. The use of an ECT in hemicraniectomized patients, as in our case, is because of the changed Anatomy poses a particular challenge and has not yet been described in the literature; from our point of view can In individual cases, ECT may be helpful for SRSE despite hemicraniectomy.
- |||||||| lacosamide / Generic mfg.
New P3 trial: A Study to Test the Long-term Use of Oral Lacosamide in Pediatric Study Participants Who Completed NCT01964560 (EP0034) or NCT00938912 (SP848) and Received Lacosamide Treatment (clinicaltrials.gov) - Nov 12, 2020
P3, N=100, Not yet recruiting, Sponsor: UCB Biopharma SRL
- | eleclazine (GS-6615) / Gilead
Journal: GS-967 and Eleclazine BlockSodium Channels in Human Induced Pluripotent Stem Cell-derived Cardiomyocytes. (Pubmed Central) - Nov 12, 2020
Sodium channel inhibition by GS-967 and eleclazine has unique features including accelerating the onset of slow inactivation and impairing recovery from inactivation. These effects combined with rapid binding and moderate unbinding kinetics explain potent use-dependent block, which we propose contributes to their observed antiarrhythmic efficacy.
- || Vimpat (lacosamide) / UCB, Daiichi Sankyo
Clinical, Observational data, Journal: A prospective, multicenter, noninterventional study in Taiwan to evaluate the safety and tolerability of lacosamide as adjunctive therapy for epilepsy in clinical practice. (Pubmed Central) - Nov 6, 2020
Results of this prospective, noninterventional study suggest that adjunctive LCM was generally safe and well tolerated in this patient group in real-world practice in Taiwan. Effectiveness was also favorable, with more than 60% of patients considered to be improved by their physician at 12 months (or final visit).
- | Vimpat (lacosamide) / UCB, Daiichi Sankyo
Journal: Cardioembolic acute cerebral micro-infarcts in the context of atrial fibrillation after low-dose intravenous infusion of lacosamide. (Pubmed Central) - Nov 3, 2020
Apixaban was initiated indefinitely five days later, and MRI showed four acute silent infarctions...If atrial fibrillation appears, the drug should be discontinued and anticoagulation should be considered according to embolic risk. Further investigation is needed in order to better categorize the risk profile of lacosamide regarding atrial fibrillation.
- |||| Nucynta (tapentadol) / Collegium Pharma, Grunenthal
Biomarker, New P2 trial: Trial in healthy subjects to investigate the effect of analgesic drug on pain processing observed by non-invasive neurophysiological measurements of human spinal cord and brainstem activity. Studio su soggetti sani volto ad indagare gli effetti di farmaci analgesici sulla elaborazione del dolore mediante misure neurofisiologiche del'attivit (EUDRACT) - Nov 3, 2020
P2, N=56, Ongoing, Sponsor: UMBERTO I - POLICLINICO DI ROMA
- || carbamazepine / Generic mfg.
Clinical, Journal: Observational multicentre study into the use of antiepileptic drugs in Spanish neurology consultations. (Pubmed Central) - Oct 31, 2020
The majority of patients received new AEDs. The combination of classic and new AEDs was more frequently prescribed to patients with refractory epilepsy or with associated comorbidities.
- || Trileptal (oxcarbazepine) / Novartis
Clinical, Journal: Analysis of pharmacotherapy regimen and costs in patients with drug-resistant epilepsy following vagus nerve stimulation therapy: a single-center study (Poland). (Pubmed Central) - Oct 28, 2020
With the rising costs of healthcare, the importance of economic efficiency is becoming increasingly relevant. VNS is a reasonable option for saving money in the healthcare system while ensuring measurable clinical and therapeutic outcomes over the long term.
- || Vimpat (lacosamide) / UCB, Daiichi Sankyo
Clinical, Observational data, Journal: Effectiveness and tolerability of lacosamide as add-on therapy in patients with brain tumor-related epilepsy: Results from a prospective, noninterventional study in European clinical practice (VIBES). (Pubmed Central) - Oct 21, 2020
P=N/A
VNS is a reasonable option for saving money in the healthcare system while ensuring measurable clinical and therapeutic outcomes over the long term. Results of this prospective, noninterventional study suggest that add-on lacosamide is effective and generally well tolerated in patients with BTRE.
- Vimpat (lacosamide) / UCB, Daiichi Sankyo
[VIRTUAL] Status Epilepticus In A Patient Post-bicoronal Craniotomy For A Brain Meningioma () - Oct 17, 2020 - Abstract #ASA2020ASA_1100;
She underwent imaging and was then intubated. Seizures were eventually controlled with levetiracetam, lacosamide, and propofol.